TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06808477: A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Sponsor: Bambusa Therapeutics · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 237 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$210,528

Rescue Site Savings

+$140,352

Unlock Full NCT06808477 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06808477 Rescue Dossier →